In lung adenocarcinoma, TRIM23 expression was shown to correlate with resistance to the chemotherapeutic agent cisplatin which was suggested to be the result of induced GLUT1/3 expression and inhibition of NF-κβ [322]. The gene discussed is TRIM23; the disease is lung adenocarcinoma.